BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA Recommended Approval For Bristol-Myers Squibb Company (BMY) BARACLUDE(TM) (entecavir)


10/19/2005 5:13:00 PM

PRINCETON, N.J., March 11 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee unanimously recommended approval of BARACLUDE(TM) (entecavir), the company's investigational oral antiviral agent under development for the treatment of chronic hepatitis B. The company presented pre-clinical and clinical data, and discussed plans for a long-term efficacy and safety program. The FDA is not bound by the committee's recommendations.

BARACLUDE is an investigational oral antiviral agent that selectively inhibits the hepatitis B virus. Bristol-Myers Squibb submitted a new drug application (NDA) to the FDA for BARACLUDE on September 29, 2004, and was granted a six-month Priority Review -- a status reserved for investigational agents that may address unmet medical needs.(1)

"Bristol-Myers Squibb is dedicated to conducting research and developing therapies designed to aid in the fight against serious diseases with significant unmet medical needs, such as chronic hepatitis B infection," said Elliott Sigal, M.D., Ph.D., chief scientific officer and president, Pharmaceutical Research Institute, Bristol-Myers Squibb. "Our global BARACLUDE clinical program spans five continents, and we are committed to advancing treatment for this disease around the world."

BARACLUDE(TM) Clinical Development Program

The FDA Advisory Committee reviewed data from the BARACLUDE clinical development program, the largest and first actively controlled trials of antivirals in chronic hepatitis B. The trials were designed to compare BARACLUDE to the most commonly used oral antiviral therapy in the United States, lamivudine, in adult patients with both chronic hepatitis B infection and evidence of active liver inflammation.(2) More than 2,300 patients from five continents participated in the BARACLUDE clinical program. A variety of different patients with chronic hepatitis B infection were studied, including both HBeAg-positive and HBeAg-negative nucleoside-naive patients and lamivudine-refractory patients.

The Phase III trial program included more than 1,500 patients in three major studies: AI463-022, which compared the investigational agent BARACLUDE to treatment with lamivudine in nucleoside-naive, HBeAg-positive chronic hepatitis B patients; AI463-027 which compared BARACLUDE to lamivudine in nucleoside-naive patients with HBeAg-negative chronic hepatitis B; and AI463- 026, which evaluated patients with lamivudine-refractory HBeAg-positive chronic hepatitis B who were either switched directly to BARACLUDE or continued to receive lamivudine.

BARACLUDE demonstrated significant histological improvement and significantly reduced viral load versus lamivudine with a similar safety profile in these three studies at 48 weeks. In these three studies, the most common adverse events of moderate to severe intensity that occurred in greater than or equal to 1% of patients treated with BARACLUDE were headache, fatigue, diarrhea, and dyspepsia.

Chronic hepatitis B is a potentially life-threatening viral infection that may lead to cirrhosis, liver failure, and liver cancer.(3) The Department of Health and Human Services recently added hepatitis B to its list of known human carcinogens.(4) More than half a million people worldwide die each year from primary liver cancer, and up to 80 percent of liver cancers are caused by chronic hepatitis B.(5)

In the United States, 12 million people (one out of 20) have been infected at some time in their lives with the hepatitis B virus, and more than five thousand Americans die from hepatitis B-related liver complications each year(6). Of those individuals, more than one million people in the U.S. have developed chronic hepatitis B infection.(6) These chronically infected persons are at highest risk of death from liver scarring (cirrhosis) and liver cancer.(7)

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Visit Bristol-Myers Squibb at http://www.bms.com/ .

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. There can be no guarantee that BARACLUDE will receive regulatory approval, or if approved, will be commercially successful. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol- Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2004 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

References 1. Center for Drug Evaluation and Research. Available at http://www.fda.gov/cder/mapp/6020-3.pdf . Accessed Feb. 23, 2005. 2. Data on file. Bristol-Myers Squibb Company. Princeton, N.J. 2004. 3. Hepatitis B Foundation. "Hepatitis B Fast Facts." Available at http://www.hepb.org/02-0119.hepb . Accessed Feb. 23, 2005. 4. Report on Carcinogens, Eleventh Edition; U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. Available at http://ntp.niehs.nih.gov/ntp/roc/toc11.html . Accessed Feb. 23, 2005. 5. Hepatitis B Foundation. "Liver Cancer". Available at http://www.hepb.org/PrinterFriendly.aspx?PageID=256&Locale=en-US . Accessed Sept. 30, 2004. 6. Hepatitis B Foundation. "Statistics." Available at http://www.hepb.org/02-0360.hepb . Accessed Feb. 23, 2005. 7. World Health Organization. "Hepatitis B Fact Sheet". Available at http://www.who.int/mediacentre/factsheets/fs204/en/ . Accessed Feb. 23, 2005. Bristol-Myers Squibb Contacts: Media Kathy Baum Tracy Furey On-site: (609) 575-0017 On-site: (609) 273-4697 Office: (609) 252-4227 Office: (609) 252-3208 Investor Relations John Elicker Blaine Davis Office: (212) 546-3775 Office: (212) 546-4631

Bristol-Myers Squibb Company

CONTACT: Kathy Baum, On-site +1-609-575-0017, Office +1-609-252-4227, orTracy Furey, On-site, +1-609-273-4697, Office +1-609-252-3208, or InvestorRelations, John Elicker, Office +1-212-546-3775, or Blaine Davis, Office+1-212-546-4631, all for Bristol-Myers Squibb Company



Read at AP
Read at BioSpace.com
Read at Medical News Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->